April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Safety And Tolerability Of Chitosan-n-acetylcysteine Eye Drops In Healthy Young Volunteers
Author Affiliations & Notes
  • Sonja Hoeller
    Research, Croma-Pharma GmbH, Leobendorf, Austria
  • Margit Hornof
    Research, Croma-Pharma GmbH, Leobendorf, Austria
  • Leopold Schmetterer
    Medical University Vienna, Vienna, Austria
  • Gerhard Garhoefer
    Medical University Vienna, Vienna, Austria
  • Footnotes
    Commercial Relationships  Sonja Hoeller, None; Margit Hornof, None; Leopold Schmetterer, None; Gerhard Garhoefer, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 3841. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sonja Hoeller, Margit Hornof, Leopold Schmetterer, Gerhard Garhoefer; Safety And Tolerability Of Chitosan-n-acetylcysteine Eye Drops In Healthy Young Volunteers. Invest. Ophthalmol. Vis. Sci. 2011;52(14):3841.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To investigate the safety and tolerability of chitosan-N-acetylcysteine eye drops in different concentrations. For this purpose the safety and tolerability will be tested in two different cohorts.

Methods: : In cohort I, one single instillation of the test product was performed. Chitosan-N-acetylcysteien eye drops were administered in 3 groups with ascending concentrations (0,025%, 0,05% and 0,1%), each comprising 6 healthy subjects. The medical product was instilled in one eye only, which was randomly chosen. The fellow eye served as control.. In cohort II the safety and tolerability of repeated instillation will be tested. 12 healthy subjects received the test product 2 times daily for 5 consecutive days. Evaluation criteria include visual acuity, corneal damages assessed with corneal staining, evaluation of eye redness using a grading scale based on standard photos.

Results: : In cohorte I a total number of 18 healthy volunteers were enrolled, male and female subjects were included in equal amounts. In concentration group 1 (0,025%) conjunctival redness occurred in two subjects in the study eye either right instillation of the medical product or 30 minutes after instillation, respectively. This conditions resolved 30 minutes after occurrence. In addition, one subject of concentration group 2 (0,05%) showed slight epithelial keratitis after fluoresceine staining, which was present up to 60 minutes after instillation of the product. However, given that the signs of the epithelial keratitis were present in both, the treated and the non treated eye this observation has been judged as unlikely related to the treatment. Moreover one subjects received topical medication for the treatment of the adverse event "bacterial conjunctivitis". Due to the fact that this adverse event occurred 4 days after the eye drops were instilled and that it appeared on the non treated eye, it was considered as "unlikely related". Evaluation of data of cohorte II is ongoing.

Conclusions: : Based on the data of the single instillation in Cohort I, the tolerability and safety of Chitosan-N-Acetylcysteine eye drops showed a favourable safety profile in healthy subjects.

Clinical Trial: : https://eudract.ema.europa.eu 2009-016565-28

Keywords: cornea: tears/tear film/dry eye • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • cornea: surface mucins 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×